LONZA GROUP AG NA SF 1
Commented by Nico Popp on October 6th, 2025 | 07:20 CEST
Biotech: Small innovations, big impact with Teva Pharmaceutical, BioNxt and Lonza Group
Anyone investing in biotech hopes to have the next big breakthrough in their portfolio: active ingredients that revolutionize everything, technologies that make a difference. In reality, however, biotechnology is characterized by many small but meaningful improvements. From an investor's perspective, it is also worth keeping an eye on these incremental advances. The reason: while the search for new, groundbreaking active ingredients is often a hit-or-miss business, small advances make it possible to generate consistent returns with relatively low capital expenditure. We present three promising business models that demonstrate the value-creation potential of incremental innovation.
Read